{"page":{"totalFilteredElements":344},"studies":[{"active":true,"description":"<p class=\"MsoNormal\">A Phase 2, Open-Label, Parallel Cohort Study of\nSubcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or\nMetastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer [CR109264]</p>","eudractNumber":"2022-000526-21","id":8484,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[{"name":"EGFR","id":"mt_1"}],"nctNumber":"NCT05498428","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2023-03-01T11:55:23+01:00","shortTitle":"PALOMA-2","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"Patientendatenintegrationsplattform der Pancreatic Cancer Alliance Bavaria (PCAB)","eudractNumber":null,"id":10521,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2023-05-26T12:31:40+02:00","shortTitle":"PCAB (Pankreasregister)","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Prostate Cancer Outcomes &#8211; Compare &amp; Reduce Variation in&#160; DKG - zertifizierten&#160; Prostatakrebszentren<div><br /></div><div>DRKS00010774<br /></div>","eudractNumber":null,"id":9703,"indications":[{"id":"pro","name":"Prostatakrebs"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2023-03-15T08:27:15+01:00","shortTitle":"PCO-D Studie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prostate Cancer Outcomes &#8211; Compare &amp; Reduce Variation in&#160; DKG - zertifizierten&#160; Prostatakrebszentren<br /><div><br /></div><div>DRKS00010774</div>","eudractNumber":null,"id":4239,"indications":[{"id":"pro","name":"Prostatakrebs"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2017-07-01T11:40:15+02:00","shortTitle":"PCO-D Studie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prostate Cancer Outcomes &#8211; Compare &amp; Reduce Variation in&#160; DKG - zertifizierten&#160; Prostatakrebszentren<br /><div><br /></div><div>DRKS00010774<br /></div>","eudractNumber":null,"id":10857,"indications":[{"id":"pro","name":"Prostatakrebs"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2022-04-01T08:48:22+02:00","shortTitle":"PCO-D Studie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prostate Cancer Outcomes &#8211; Compare &amp; Reduce Variation in&#160; DKG - zertifizierten&#160; Prostatakrebszentren<br /><div><br /></div><div>DRKS00010774</div>","eudractNumber":null,"id":4307,"indications":[{"id":"pro","name":"Prostatakrebs"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2017-01-03T12:47:13+01:00","shortTitle":"PCO-D Studie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prostate Cancer Outcomes &#8211; Compare &amp; Reduce Variation in&#160; DKG - zertifizierten&#160; Prostatakrebszentren<br /><div><br /></div><div>DRKS00010774</div>","eudractNumber":null,"id":10618,"indications":[{"id":"pro","name":"Prostatakrebs"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2021-08-05T09:22:14+02:00","shortTitle":"PCO-D Studie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prostate Cancer Outcomes &#8211; Compare &amp; Reduce Variation in&#160; DKG - zertifizierten&#160; Prostatakrebszentren<br /><div><br /></div><div>DRKS00010774<br /></div>","eudractNumber":null,"id":4571,"indications":[{"id":"pro","name":"Prostatakrebs"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2018-12-02T13:28:48+01:00","shortTitle":"PCO-D Studie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Pr&#228;vention von fr&#252;hen Darmkrebserkrankungen - PEARL","eudractNumber":null,"id":11520,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[],"nctNumber":"NCT05541601","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2022-10-10T09:48:39+02:00","shortTitle":"PEARL","therapeutical":false,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<div>PERSUASION</div><div>New Prospective Expanded German Registry of Incidental Gallbladder Carcinoma (PERSUASION) a permanent platform including all kind of biliary tract cancers (BTC)</div>","eudractNumber":null,"id":9177,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"}],"mutations":[],"nctNumber":"NCT04896931","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2023-01-30T21:22:13+01:00","shortTitle":"PERSUASION","therapeutical":false,"therapyLines":[]}]}